Video

Dr. Ledermann on the Results of the ARIEL3 Trial in Ovarian Cancer

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the results of the ARIEL3 trial in ovarian cancer.

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the results of the ARIEL3 trial in ovarian cancer.

Results of ARIEL3 showed that there was a significant improvement in progression-free survival with maintenance rucaparib in the BRCA-mutant population, the homologous recombination deficient (HRD) cohort, and the all-comers cohort.

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Premal Thaker, MD, MS
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Kathleen N. Moore, MD, MS
Casey M. Cosgrove, MD, gynecologic oncologist, assistant professor, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center—James Cancer Hospital and Solove Research Institute